Sylvie Morgeaux
Pasteur Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sylvie Morgeaux.
Biologicals | 1990
Pierre Perrin; Sylvie Morgeaux; Pierre Sureau
The replacement of the in vivo potency test (NIH test) for rabies vaccine evaluation by in vitro methods is at present discussed in many reports and also by WHO expert working groups. For this purpose, in vitro glycoprotein titration has been proposed. Among the different glycoprotein assays, we have studied two ELISA methods (immunocapture and direct plate coating with the antigen to be tested) using neutralizing mono- and polyclonal antibodies. In our view, the immunocapture method based on the use of a neutralizing monoclonal anti-glycoprotein antibody seems to be a convenient tool for the determination of the in vitro potency of rabies vaccine and of the products corresponding to the different steps of their production process.
Vaccine | 1996
Nathalie Castignolles; Sylvie Morgeaux; Corinne Gontier-Jallet; Daniel Samain; Didier Betbeder; Pierre Perrin
Biovectors (BV) are a new family of protein carriers. They are nanoparticles of polymerized polysaccharides substituted with phosphate residues and surrounded by covalently bound lipid molecules (palmitic acid). The effect of BV was tested on the immunogenicity of rabies antigens. Biovectors enhanced the production of antibody induced by both rabies glycoprotein and ribonucleoprotein. Moreover, they enhanced the protective activity of an experimental rabies vaccine composed of inactivated and purified virus. The isotype profile of antibody produced in vivo was not modified when BV were mixed with rabies antigens. To clarify the mechanism of the adjuvant/ immunostimulation effect of BV, two types of approach were used: (1) analysis of the antibody response when antigen and BV were injected separately; (2) determination of the nature of cells involved in the proliferation in vitro of murine splenocytes in the presence of BV. The enhancing effect of BV on antibody production was highest when mixed with antigens. In vitro BV induced the proliferation of B cells. These findings suggest that BV have immunostimulating properties in addition to their probable depot and/or antigen-presentation effect which explain in part their adjuvant activity.
Vaccine | 1993
Sylvie Morgeaux; Noël Tordo; Gontier C; Pierre Perrin
The effects of beta-propiolactone (BPL), an alkylating and virus inactivating agent, on the structural and in vitro biological properties of different DNA preparations from BHK-21 cells were investigated. Both uninfected and rabies virus-infected cells were used. Purified cellular DNA (celDNA) was used as the reference, and supernatants from infected cells were treated with BPL. For structural and biological studies three types of DNA preparation were tested: celDNA; purified DNA from cell (infected or uninfected) supernatant (pcsDNA) with or without BPL treatment; and residual cell DNA present in purified rabies virus (inactivated or not) preparations. Rabies infection and BPL (diluted 1:4000) treatment induced modifications in the structure of the three DNA types, including strand breaks and nicks. The damage to the DNA structure by BPL modifies the biological properties of the pcsDNA appraised by its ability to serve as the template in vitro for different polymerases. When rabies virus was inactivated with BPL diluted 1:1000 the DNA damage increased dramatically: small double-stranded DNA fragments (50-200 base pairs) were generated which could not function as templates for polymerases.
Biologicals | 1991
Marie-Line Joffret; Carlos Zanetti; Sylvie Morgeaux; Claude Leclerc; Pierre Sureau; Pierre Perrin
The potency of different rabies vaccines was measured via cell mediated immunity (CMI) assessed by the production of interleukin-2 (IL-2) by CD4+CD8- lymphocytes. IL-2 production by splenocytes from mice immunized with various vaccines was measured following in vitro stimulation with antigens from different rabies and rabies-related strains. IL-2 production was specific, reproducible and correlated with the vaccine protective activity as determined by the pre-exposure NIH test. Our results suggest that measurement of IL-2 production could be used for the appraisal of rabies vaccine potency.
Vaccine | 1990
Marie-Line Joffret; Sylvie Morgeaux; Claude Leclerc; Daniel Oth; Carlos Zanetti; Pierre Sureau; Pierre Perrin
The present report demonstrates that liposomes increase the interleukin-2 (IL-2) dependent proliferation of cytotoxic T-lymphocyte line (CTLL) cells used for the measurement of IL-2 activity. This effect was better observed with suboptimal doses of IL-2 and low concentrations of lipids. The increased IL-2 dependent proliferation is not due to a direct effect of liposomes on CTLL cells but rather to an interaction between IL-2 and liposomes. An interaction between IL-2 and components of fetal calf serum is also demonstrated. The results indicate that liposomes may interfere with IL-2 bioassay but also show the possibility of potentiating IL-2 activity for therapeutic purposes.
Vaccine | 2013
Richard Gibert; Monique Alberti; Bertrand Poirier; Corinne Jallet; Noël Tordo; Sylvie Morgeaux
To assess the quality of vaccine batches before release, international regulation requires the control of potency of each lot of human rabies vaccines by the in vivo NIH challenge test. Meanwhile, the 3Rs strategy for animal testing encourages the replacement of the in vivo potency test by an in vitro assay. Consequently, since more than 10 years, an ELISA method has been implemented by ANSM in parallel to the NIH test for rabies vaccines lots. It consists in the evaluation of the glycoprotein content using a monoclonal antibody recognizing the trimeric native form of the glycoprotein. This ELISA method is able 1) to monitor the consistency of production with a similar profile than the NIH; 2) to detect a low quantity of glycoprotein in vaccines and 3) to agree with the manufacturers NIH results by declaring a non compliant batch. This ELISA which characterizes the immunogenic form of the glycoprotein formulated in vaccines seems to be relevant to replace the NIH test and is a promising candidate to be standardized by a collaborative study.
Vaccine | 2017
Sylvie Morgeaux; Bertrand Poirier; C. Ian Ragan; Dianna E. Wilkinson; Ulrich Arabin; Françoise Guinet-Morlot; Robin Levis; Heidi Meyer; Patrice Riou; Shahjahan Shaid; Dmitriy V. Volokhov; Noël Tordo; Jean-Michel Chapsal
Three different ELISAs quantifying rabies glycoprotein were evaluated as in vitro alternatives to the National Institutes of Health (NIH) in vivo potency test for batch release of human rabies vaccines. The evaluation was carried out as an international collaborative study supported by the European Partnership for Alternatives to Animal Testing (EPAA). This pre-validation study, the results of which are presented in this paper, compared three different ELISA designs, assessing their within- and between-laboratory precision. One of the ELISA designs was proposed to the European Directorate for the Quality of Medicines & HealthCare (EDQM) and accepted for an international collaborative study under the umbrella of the Biological Standardisation Programme.
Animal Cell TechnologyProducts of Today, Prospects for Tomorrow | 1994
Sylvie Morgeaux; Noël Tordo; O.-W. Merten; Pierre Perrin
ABSTRACT In the future, numerous biologicals (including vaccine) will be produced by recombinant DNA technology in continuous cell lines (CCLs). Strict criteria exist for the acceptance of these biologicals for human use, notably concerning the residual DNA (rDNA) from cell origin. The use of inactivating agents, which can react with DNA, may lead to revise these criteria. The experimental rabies vaccine prepared from the BHK-21 CCL was used as a model for studying the effects of an inactivating and alkylating agent (beta-propiolactone: BPL) on structural and in vitro biological properties of rDNA. Both rabies infection and at a larger extent BPL treatment induced breaks and nicks in DNA strands. After BPL treatment, the capability of DNA to be used as template for different polymerases decreased dramatically according to BPL concentration. This result indicate that both a quantitative (concentration measurement) and a qualitative (determination of rDNA biological activity) analyses might be taken into account for the acceptance of biologicals.
Biologicals | 1995
Pierre Perrin; Sylvie Morgeaux
Vaccine | 2016
Jehanara Korimbocus; Nicolas Dehay; Noël Tordo; François Cano; Sylvie Morgeaux
Collaboration
Dive into the Sylvie Morgeaux's collaboration.
Agence française de sécurité sanitaire des produits de santé
View shared research outputs